Physician profile
Jay D Markham
NPI 1427022508
$2,227.55
in general payments reported to CMS, 2019-2025
18 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $62.51 · 2021: $363 · 2022: $342 · 2023: $434 · 2024: $441 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $442.52 | 2019-2025 | |
| Pfizer INC. | $360.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $259.33 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.38 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $159.01 | 2019-2022 | |
| Amgen INC. | $155.29 | 2019-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $132.24 | 2019-2025 | Onpattro |
| Abbott Laboratories | $116.62 | 2021 | |
| Bridgebio Pharma, INC. | $78.30 | 2025 | Attruby |
| Heartflow, INC. | $60.35 | 2023 | Ffrct |
| Merck Sharp & Dohme LLC | $59.82 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $55.00 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $39.65 | 2019-2022 | |
| Cardiva Medical, INC. | $26.47 | 2022 | |
| Lundbeck LLC | $19.93 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $19.17 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $16.29 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $15.91 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Markham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.